Neridronic acid for treating complex regional pain syndrome

Abstract

Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.

What is claimed is: 
     
         1 . A method of treating complex regional pain syndrome (CRPS), comprising administering a parenteral dose of about 5 mg to about 200 mg of neridronic acid, in an acid form or a salt form, to a human being suffering from complex regional pain syndrome, wherein the human being has a pain score of at least about 4 on the 0-10 numeric rating scale (NRS) before the treatment, and wherein bone fracture was a predisposing event for CRPS. 
     
     
         2 . The method of  claim 1 , wherein the human being is suffering from complex regional pain syndrome type I. 
     
     
         3 . The method of  claim 1 , wherein the human being is suffering from complex regional pain syndrome type II. 
     
     
         4 . The method of  claim 1 , wherein the neridronic acid is parenterally administered daily, weekly, monthly, every two months, every three months, once a year, or twice a year. 
     
     
         5 . The method of  claim 1 , wherein the neridronic acid is administered intravenously. 
     
     
         6 . The method of  claim 1 , wherein the neridronic acid is administered in a dosage form that is a dispersion, a suspension, or a solution. 
     
     
         7 . The method of  claim 1 , wherein the neridronic acid is administered by controlled release means, sustained release means, or delivery devices. 
     
     
         8 . The method of  claim 4 , wherein the neridronic acid is parenterally administered daily. 
     
     
         9 . The method of  claim 8 , wherein about 10 mg to about 150 mg of the neridronic acid is parenterally administered daily. 
     
     
         10 . The method of  claim 9 , wherein about 100 mg of the neridronic acid is parenterally administered daily. 
     
     
         11 . The method of  claim 10 , wherein about 100 mg of the neridronic acid is parenterally administered daily 2 to 4 times within 10 days. 
     
     
         12 . The method of  claim 5 , wherein about 100 mg of the neridronic acid is administered intravenously. 
     
     
         13 . The method of  claim 12 , wherein about 100 mg of the neridronic acid is administered intravenously every 3 days. 
     
     
         14 . The method of  claim 13 , wherein about 100 mg of the neridronic acid is administered intravenously every 3 days for 4 to 6 times. 
     
     
         15 . The method of  claim 4 , wherein the neridronic acid is parenterally administered weekly. 
     
     
         16 . The method of  claim 15 , wherein the weekly parenteral dose of the neridronic acid is about 5 mg to about 500 mg. 
     
     
         17 . The method of  claim 5 , wherein about 200 mg to about 500 mg of neridronic acid is intravenously administered weekly. 
     
     
         18 . The method of  claim 1 , wherein the human being is at age of about 40 years to about 70 years. 
     
     
         19 . The method of  claim 1 , wherein the human being has debilitating pain before treatment. 
     
     
         20 . The method of  claim 1 , wherein the human being has a pain intensity of at least 7 on the 0-10 NRS or greater before treatment. 
     
     
         21 . The method of  claim 1 , wherein the human being has not been treated with a bisphosphonate therapy before the treatment of the neridronic acid. 
     
     
         22 . The method of  claim 1 , wherein the treatment with the neridronic acid is effective in reducing pain. 
     
     
         23 . The method of  claim 1 , wherein the human being has edema associated with CRPS, and the treatment with the neridronic acid is effective in reducing edema.